A Phase 2/3 clinical trial with zanzalintinib versus everolimus.

  • Research type

    Research Study

  • Full title

    A Phase 2/3, Multicenter, Randomized Open-label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

  • IRAS ID

    1011801

  • Contact name

    Simone Mangini

  • Contact email

    smangini@exelixis.com

  • Clinicaltrials.gov Identifier

    NCT06943755

  • Research summary

    This is a multicenter, global, randomized, open-label comparator-controlled, adaptive Phase 2/3 study in participants both male and female ≥ 18 years.
    The purpose of the study is to evaluate Zanzalintinib alone or in combination with everolimus to treat multiple types of cancers. The primary objective of this trial is to evaluate progression-free survival (PFS) of zanzalintinib versus everolimus in all randomised participants who have well-differentiated unresectable, locally advanced or metastatic extra-pancreatic (tumor that does not include the pancreas) neuroendocrine tumours (epNET) or pancreatic neuroendocrine tumors (pNET) who have received up to one prior systemic treatment.
    Participants who enter the study will be put into one of two possible treatment groups. Participants in one group will take zanzalintinib. Participants in the other group will receive a total dose of 10 mg of everolimus.
    Safety evaluations will include assessments of adverse events (AEs), physical examinations, vital signs, Eastern Cooperative Oncology Group (ECOG) performance status, ECHO, 12-lead electrocardiograms (ECGs), and clinical laboratory tests.
    About 440 participants are expected to take part in this study globally. Participants may be in this study for up to 60 months (or 5 years).

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference

    25/LO/0673

  • Date of REC Opinion

    27 Oct 2025

  • REC opinion

    Further Information Favourable Opinion